Literature DB >> 24618538

Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.

Henning Tiede1, Natascha Sommer, Katrin Milger, Robert Voswinckel, Dirk Bandorski, Ralph T Schermuly, Norbert Weissmann, Friedrich Grimminger, Werner Seeger, Hossein A Ghofrani.   

Abstract

Abstract Hemodynamic measurements provide important parameters for determining prognosis and therapy in patients with pulmonary arterial hypertension (PAH). Current guidelines do not incorporate the possible predictive value of individual changes in hemodynamic variables during the disease time course, and there is no consensus about the time point for hemodynamic reevaluation. We aimed to assess the long-term prognostic value of short-term changes in hemodynamic parameters. The study included 122 patients with PAH from the Giessen Pulmonary Hypertension Registry who underwent hemodynamic evaluation at baseline and at 16 weeks (±2.5 standard deviations [SDs]; range: 4-29 weeks) after initial assessment. At baseline, mean pulmonary vascular resistance (PVR) was 1,109 dyn s cm(-5), and 82% of patients were in World Health Organization (WHO) functional class III or IV. Fifty patients died, and 2 underwent lung transplantation during long-term observation (≤10 years; mean: 4.7 years). Kaplan-Meier estimates for transplant-free survival were 93.3%, 76.1%, 57.8%, and 53.1% at 1, 3, 5, and 7 years, respectively. When assigned to prognostic groups, improvements in cardiac output of >0.22 L min(-1) (hazard ratio [HR]: 2.05; [Formula: see text]) and a decrease in PVR of >176 dyn s cm(-5) (HR: 1.89; [Formula: see text]) at 4-29 weeks were associated with long-term transplant-free survival. Changes in mean pulmonary arterial pressure did not predict long-term prognosis. Of 2 noninvasive parameters assessed in this selected patient group, change in WHO functional class, but not in 6-minute walk distance, predicted long-term prognosis. Short-term assessment of changes in hemodynamic parameters at [Formula: see text] after initial invasive evaluation is useful to determine long-term prognosis in patients with PAH.

Entities:  

Year:  2013        PMID: 24618538      PMCID: PMC4070816          DOI: 10.1086/674338

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  27 in total

1.  Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.

Authors:  Roberto Badagliacca; Beatrice Pezzuto; Roberto Poscia; Massimo Mancone; Silvia Papa; Serena Marcon; Gabriele Valli; Gennaro Sardella; Fabio Ferrante; Carlo Iacoboni; Daniela Parola; Francesco Fedele; Carmine Dario Vizza
Journal:  J Heart Lung Transplant       Date:  2012-01-29       Impact factor: 10.247

2.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

3.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.

Authors:  Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

Review 4.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension.

Authors:  Gert-Jan Mauritz; Dimitris Rizopoulos; Herman Groepenhoff; Henning Tiede; Janine Felix; Paul Eilers; Joachim Bosboom; Pieter E Postmus; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  Am J Cardiol       Date:  2011-09-03       Impact factor: 2.778

Review 6.  The study of risk in pulmonary arterial hypertension.

Authors:  Lewis J Rubin; Gerald Simonneau; David Badesch; Nazzareno Galiè; Marc Humbert; Anne Keogh; Joseph Massaro; Marco Matucci Cerinic; Olivier Sitbon; Steven Kymes
Journal:  Eur Respir Rev       Date:  2012-09-01

7.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

8.  Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.

Authors:  Jason S Fritz; Christiana Blair; Ronald J Oudiz; Christopher Dufton; Horst Olschewski; Darrin Despain; Hunter Gillies; Steven M Kawut
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 10.  Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.

Authors:  O Sitbon; N Galiè
Journal:  Eur Respir Rev       Date:  2010-12
View more
  6 in total

Review 1.  Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

Authors:  Alison M MacKenzie; Andrew J Peacock
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 2.  Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Authors:  Bradley A Maron
Journal:  Can J Cardiol       Date:  2014-09-28       Impact factor: 5.223

3.  SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Pavel Jansa; Tomás Pulido; Richard N Channick; Marion Delcroix; Hossein-Ardeschir Ghofrani; Franck-Olivier Le Brun; Sanjay Mehta; Loïc Perchenet; Lewis J Rubin; B K S Sastry; Gérald Simonneau; Olivier Sitbon; Rogério Souza; Adam Torbicki
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

4.  The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.

Authors:  Catherine G Billings; Robert Lewis; Judith A Hurdman; Robin Condliffe; Charlie A Elliot; A A Roger Thompson; Ian A Smith; Matthew Austin; Iain J Armstrong; Neil Hamilton; Athanasios Charalampopoulos; Ian Sabroe; Andrew J Swift; Alexander M Rothman; Jim M Wild; Allan Lawrie; Judith C Waterhouse; David G Kiely
Journal:  Pulm Circ       Date:  2019 Apr-Jun       Impact factor: 3.017

Review 5.  The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.

Authors:  Samantha L Wronski; Margaret Mordin; Kim Kelley; Rebekah H Anguiano; Peter Classi; Eric Shen; Scott Manaker
Journal:  Lung       Date:  2019-11-13       Impact factor: 2.584

Review 6.  Pulmonary Hypertension and Indicators of Right Ventricular Function.

Authors:  Célia von Siebenthal; John-David Aubert; Periklis Mitsakis; Patrick Yerly; John O Prior; Laurent Pierre Nicod
Journal:  Front Med (Lausanne)       Date:  2016-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.